As part of the Endourological Society's (ES) initiative to continuously enhance the field of endourology, the second annual census was circulated after the World Congress of Endourology and Uro-Technology 2022 (WCET22). An anonymous survey was created using Qualtrics XM and was disseminated via email to all ES members ( = 1502) between October 4, 2022, and January 26, 2023. A total of 46 questions were included in the survey and covered different aspects, including demographics, practice patterns, satisfaction, impact of COVID-19, WCET22 attendance, and future opportunities. A total of 404 (26.9%) ES members (91.8% male and 8.2% female), representing 63 different countries, participated in the survey. Fellowship-trained endourologists constituted 58.9% of respondents, and the most common practice setting was academic (55.2%). The most common practice scope was complex retrograde endoscopy (83.4%), followed by percutaneous nephrolithotomy (79.5%) and medical management of urolithiasis (72.5%). Work schedules were variable, with 51.1% working 40-60 hours/week and 35.3% working >60 hours/week. More than 80% were satisfied with t heir practice; however, 42.4% indicated that COVID-19 made satisfaction worse. Of the participants, 49.5% were satisfied with their compensation, and 7.3% plan to retire within the next 5 years. When asked about the future of endourology, 92.9% had a positive outlook. Of the respondents, only 36.8% attended WCET22, with the most chosen reason for attendance being an interest in learning new research and technology. For lack of attendance, the cost of travel and lodging was reported as a determining factor by 45.4%. These survey results report important trends within the field of endourology and demonstrate the robust outlook of ES members for the future. By demonstrating important practice patterns and member needs, this information can be used to improve the responsiveness of its members and to continually strengthen the ES.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/end.2024.0512 | DOI Listing |
Eur Urol Focus
November 2024
Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; University Vita-Salute San Raffaele, Milan, Italy; Young Academic Urologists Endourology & Urolithiasis Working Group, European Association of Urology, Arnhem, The Netherlands; Progressive Endourological Association for Research and Leading Solutions (PEARLS), Paris, France. Electronic address:
J Endourol
November 2024
Division of Urology, Department of Surgery, Prisma Health Midlands, University of South Carolina School of Medicine, Columbia, South Carolina, USA.
Arch Esp Urol
August 2024
Department of Urology, University Hospital Southampton, SO16 Southampton, UK.
Maedica (Bucur)
June 2024
"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Introduction: Urolithiasis is a serious health issue that is constantly getting worse around the world. In relation to laser lithotripsy, new techniques and technological advancements have emerged, giving urologists a wide range of choices for treating stone disease. The objective of the present review is to provide an overview of the most current developments and show how effective they are for reducing complications and boosting surgical effectiveness.
View Article and Find Full Text PDFJ Endourol
September 2024
Zucker School of Medicine of Hofstra/Northwell, Smith Institute for Urology, Lake Success, New York, USA.
To characterize the trends in female representation in the endourology fellowship match compared with the urology residency match. Available deidentified match data from 2017 to 2022 was obtained from the American Urological Association and Endourology Society annual census data. We evaluated gender-specific participation in the urology residency and endourology fellowship match and compared differences in the trends over the last 6 years.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!